MX2022006308A - Derivados de carbazol polimorfos y usos de los mismos. - Google Patents
Derivados de carbazol polimorfos y usos de los mismos.Info
- Publication number
- MX2022006308A MX2022006308A MX2022006308A MX2022006308A MX2022006308A MX 2022006308 A MX2022006308 A MX 2022006308A MX 2022006308 A MX2022006308 A MX 2022006308A MX 2022006308 A MX2022006308 A MX 2022006308A MX 2022006308 A MX2022006308 A MX 2022006308A
- Authority
- MX
- Mexico
- Prior art keywords
- polymorphic
- carbazole derivatives
- ahr
- involved
- compositions
- Prior art date
Links
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 title 1
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 abstract 3
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 1
- 239000012458 free base Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940481P | 2019-11-26 | 2019-11-26 | |
| PCT/US2020/062197 WO2021108528A1 (en) | 2019-11-26 | 2020-11-25 | Polymorphic carbazole derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006308A true MX2022006308A (es) | 2022-06-22 |
Family
ID=73856339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006308A MX2022006308A (es) | 2019-11-26 | 2020-11-25 | Derivados de carbazol polimorfos y usos de los mismos. |
| MX2026004523A MX2026004523A (es) | 2019-11-26 | 2022-05-25 | Derivados de carbazol polimorfos y usos de los mismos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2026004523A MX2026004523A (es) | 2019-11-26 | 2022-05-25 | Derivados de carbazol polimorfos y usos de los mismos |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11591339B2 (enExample) |
| EP (2) | EP4529955A3 (enExample) |
| JP (2) | JP2023502531A (enExample) |
| CN (2) | CN122404338A (enExample) |
| AU (1) | AU2020394424A1 (enExample) |
| CA (1) | CA3159317A1 (enExample) |
| ES (1) | ES3028099T3 (enExample) |
| FI (1) | FI4065582T3 (enExample) |
| IL (1) | IL293326A (enExample) |
| MX (2) | MX2022006308A (enExample) |
| PL (1) | PL4065582T3 (enExample) |
| PT (1) | PT4065582T (enExample) |
| WO (1) | WO2021108528A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| AU2020394424A1 (en) | 2019-11-26 | 2022-06-16 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| WO2021236717A1 (en) | 2020-05-20 | 2021-11-25 | Senda Biosciences, Inc. | Fused imidazole derivatives as ahr antagonists |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3274118A (en) | 1962-01-22 | 1966-09-20 | Lithium Corp | Preparation of stable non-pyrophoric organometallic compositions |
| US5721356A (en) | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
| US5962473A (en) | 1996-08-16 | 1999-10-05 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| BR0115995A (pt) | 2000-12-19 | 2004-01-13 | Merck Patent Gmbh | Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina |
| US20040235877A1 (en) | 2001-09-14 | 2004-11-25 | Natsuki Ishizuka | Novel use of tricyclic compound |
| KR20050058507A (ko) | 2002-09-04 | 2005-06-16 | 쉐링 코포레이션 | 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 |
| WO2004026867A2 (en) | 2002-09-19 | 2004-04-01 | Schering Corporation | Imidazopyridines as cyclin dependent kinase inhibitors |
| JP4895806B2 (ja) | 2003-04-09 | 2012-03-14 | エクセリクシス， インク． | Ｔｉｅ−２モジュレータと使用方法 |
| TW200536536A (en) | 2004-02-25 | 2005-11-16 | Schering Corp | Pyrazolotriazines as kinase inhibitors |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| KR20070118068A (ko) | 2004-11-23 | 2007-12-13 | 레디 유에스 테라퓨틱스 인코포레이티드 | 신규의 이원 헤테로고리 화합물, 그 제조방법 및 이들을포함하는 조성물 |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| DK1879573T3 (da) | 2005-05-10 | 2013-02-25 | Incyte Corp | Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| CA2663057C (en) | 2006-09-19 | 2015-12-08 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US7750007B2 (en) | 2006-11-06 | 2010-07-06 | Supergen, Inc. | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| EP2229390B1 (en) | 2007-12-14 | 2014-04-09 | F. Hoffmann-La Roche AG | Novel imidazoý1,2-a¨pyridine and imidazoý1,2-b¨pyridazine derivatives |
| EP2296789A1 (fr) | 2008-05-29 | 2011-03-23 | Saint-Gobain Centre de Recherches et d'Etudes Européen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| PL2509602T3 (pl) | 2009-12-04 | 2017-08-31 | Senhwa Biosciences, Inc. | Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2 |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| WO2012044562A2 (en) | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine pde10 inhibitors |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| AU2012244550C1 (en) | 2011-04-21 | 2017-06-22 | Origenis Gmbh | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| WO2013086436A1 (en) | 2011-12-08 | 2013-06-13 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| AR090650A1 (es) | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014060112A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| WO2014138485A1 (en) | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| US11427600B2 (en) * | 2014-06-27 | 2022-08-30 | Nogra Pharma Limited | Aryl receptor modulators and methods of making and using the same |
| CN108290855A (zh) | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途 |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| US10457683B2 (en) | 2017-04-12 | 2019-10-29 | Magenta Therapeutics Inc. | Aryl hydrocarbon receptor antagonists and uses thereof |
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| KR20210110566A (ko) | 2018-10-16 | 2021-09-08 | 이케나 온콜로지, 인코포레이티드 | 인돌 ahr 저해제 및 이의 용도 |
| EP4065090A1 (en) | 2019-11-26 | 2022-10-05 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
| AU2020394424A1 (en) | 2019-11-26 | 2022-06-16 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| BR112022013673A2 (pt) | 2020-01-10 | 2022-09-13 | Ikena Oncology Inc | Inibidores de ahr e seus usos |
| CA3196535A1 (en) | 2020-10-28 | 2022-05-05 | Alfredo C. Castro | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
-
2020
- 2020-11-25 AU AU2020394424A patent/AU2020394424A1/en not_active Abandoned
- 2020-11-25 CA CA3159317A patent/CA3159317A1/en active Pending
- 2020-11-25 CN CN202610357767.2A patent/CN122404338A/zh active Pending
- 2020-11-25 WO PCT/US2020/062197 patent/WO2021108528A1/en not_active Ceased
- 2020-11-25 PL PL20828454.7T patent/PL4065582T3/pl unknown
- 2020-11-25 CN CN202080092193.1A patent/CN115279764B/zh active Active
- 2020-11-25 IL IL293326A patent/IL293326A/en unknown
- 2020-11-25 PT PT208284547T patent/PT4065582T/pt unknown
- 2020-11-25 ES ES20828454T patent/ES3028099T3/es active Active
- 2020-11-25 FI FIEP20828454.7T patent/FI4065582T3/fi active
- 2020-11-25 MX MX2022006308A patent/MX2022006308A/es unknown
- 2020-11-25 EP EP25158597.2A patent/EP4529955A3/en active Pending
- 2020-11-25 JP JP2022530741A patent/JP2023502531A/ja active Pending
- 2020-11-25 EP EP20828454.7A patent/EP4065582B1/en active Active
- 2020-11-25 US US17/104,237 patent/US11591339B2/en active Active
-
2022
- 2022-05-25 MX MX2026004523A patent/MX2026004523A/es unknown
-
2023
- 2023-01-19 US US18/156,562 patent/US12162884B2/en active Active
-
2024
- 2024-10-21 US US18/921,463 patent/US20250276975A1/en active Pending
-
2025
- 2025-05-20 JP JP2025084133A patent/JP2025113368A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210253579A1 (en) | 2021-08-19 |
| US20230286990A1 (en) | 2023-09-14 |
| JP2023502531A (ja) | 2023-01-24 |
| EP4529955A2 (en) | 2025-04-02 |
| PL4065582T3 (pl) | 2025-08-18 |
| PT4065582T (pt) | 2025-05-22 |
| ES3028099T3 (en) | 2025-06-18 |
| AU2020394424A1 (en) | 2022-06-16 |
| US12162884B2 (en) | 2024-12-10 |
| EP4065582B1 (en) | 2025-02-19 |
| EP4065582A1 (en) | 2022-10-05 |
| CA3159317A1 (en) | 2021-06-03 |
| MX2026004523A (es) | 2026-05-04 |
| WO2021108528A1 (en) | 2021-06-03 |
| US11591339B2 (en) | 2023-02-28 |
| JP2025113368A (ja) | 2025-08-01 |
| CN115279764B (zh) | 2026-04-07 |
| IL293326A (en) | 2022-07-01 |
| CN122404338A (zh) | 2026-07-17 |
| KR20220125231A (ko) | 2022-09-14 |
| US20250276975A1 (en) | 2025-09-04 |
| CN115279764A (zh) | 2022-11-01 |
| EP4529955A3 (en) | 2025-07-16 |
| FI4065582T3 (fi) | 2025-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019011693A (es) | Compuestos que inhiben la proteina mcl-1. | |
| ECSP24026455A (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| CL2020001546A1 (es) | Compuestos de 4-azaindol. | |
| CL2019000368A1 (es) | Inhibidores de cdk2/4/6. | |
| CY1123595T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 | |
| ECSP20060827A (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b | |
| CL2019003015A1 (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
| CL2018001899A1 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
| CL2022000093A1 (es) | Imidazopirimidinas como inhibidores de eed y uso de estas | |
| MX2017012558A (es) | Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para su uso. | |
| CU20180152A7 (es) | Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| CU20180006A7 (es) | Compuestos de indazaol y azaindazol como inhibidores de irak-4 | |
| CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
| CO2018006164A2 (es) | Compuestos útiles como inhibidores de cinasa | |
| CL2021000292A1 (es) | Benzimidazoles sustituidos como inhibidores de pad4. | |
| CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
| CL2020001107A1 (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. | |
| CU24550B1 (es) | Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos | |
| MX2019003310A (es) | Inhibidores de dopamina-b-hidroxilasa. | |
| CO2020006542A2 (es) | Profármacos de creatina, composiciones y métodos de uso de estos | |
| CU24553B1 (es) | Compuestos de indazol útiles en lesiones de tendones y/o ligamentos | |
| EP4529955A3 (en) | Polymorphic carbazole derivatives and uses thereof |